BioCentury | Oct 24, 2013
Strategy

Synaptic synopsis

...Therapeutics Ltd. mGluR5 modulator Discovery ASD; depression Other receptor targets s-1 Receptor M's Science Corp. SA4503...
BioCentury | Mar 17, 2008
Company News

M’s Science Corp., Eisai deal

...M’s granted Eisai an option to rights to develop and commercialize SA4503 , a small molecule...
BioCentury | Feb 4, 2008
Clinical News

SA4503: Phase II started

...M's Science began a double-blind, international Phase II trial to compare SA4503 to placebo in 60...
...to it in early 2006. M's Science Corp. , Kobe City, Japan Product: SA4503 (formerly AGY-94806...
BioCentury | Jul 26, 2004
Product Development

Different strokes for AGY

...picks: stroke. AGY is taking a different tack, and plans to develop its newly acquired AGY-94806...
...a partnership with M's Science (Kobe, Japan) for the other. AGY received rights to develop AGY-94806...
...the end of 2005. AGY has in vitro data showing that neuronal cells treated with AGY-94806...
BioCentury | Jul 26, 2004
Company News

AGY Therapeutics, M's Science deal

...M's granted AGY exclusive rights to develop and commercialize AGY-94806 (or SA4503 ), a small molecule...
...retain rights for certain CNS indications. AGY plans to start a Phase II trial of AGY-94806...
BioCentury | Jul 20, 2004
Company News

AGY licenses stroke compound from M's

...Kobe, Japan) granted AGY (South San Francisco, Calif.) exclusive rights to develop and commercialize AGY-94806 (SA4503...
...retain rights for certain CNS indications. AGY plans to start a Phase II trial of AGY-94806...
...addition, AGY has rights to the compound to treat traumatic brain and spinal cord injury. AGY-94806...
Items per page:
1 - 6 of 6